Entera Bio Ltd.
ENTXEntera Bio Ltd. in brief
Entera Bio Ltd. is a listed company in the Biotechnology industry, based in Israel. Its market value was $543 M on 30 October 2026, which makes it the 12,196th largest listed company in the world and the 133rd largest in Israel on this site. In the year to December 2025 it had sales of $0 M and a net loss of $11 M. It employs about 22 people and Miranda Jayne Toledano is its chief executive. Its shares trade under the symbol ENTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Entera Bio Ltd.
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap. From a technical standpoint, oral delivery of peptides and therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream. We leverage our N-Tab® platform, which is designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream.
From the company's annual report filed with the US SEC: read the report
Entera Bio Ltd. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 25 June 2018.
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 5 years on record.
Events of Entera Bio Ltd. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #314 (Jan 2020) · #342 (Jan 2021) · #327 (Jan 2022) · #416 (Dec 2022) · #396 (Jul 2023) · #381 (Jan 2024) · #38 (Mar 2026) · #134 (Aug 2026) · #146 (Oct 2026) · #133 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 13582.7×
- Price / book
- 41.5×
- Free cash flow yield
- -1.4%
- Net margin
- -28600.0%
- Operating margin
- -28825.0%
- Return on equity
- -87.3%
- Liabilities / assets
- 18.1%
- Net debt
- $-8M
- Revenue growth
- -77.8%
- R&D / revenue
- 15000.0%
- Revenue per employee
- $2 K
- Profit per employee
- $-520 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -77.8% | $-12M | $-11M | -28600.0% |
| Dec 2024 | $0M | — | $-10M | $-10M | -5300.0% |
| Dec 2023 | — | — | $-9M | $-9M | — |
| Dec 2022 | $0M | -77.2% | $-13M | $-13M | -10053.8% |
| Dec 2021 | $1M | +58.3% | $-12M | $-12M | -2138.6% |
| Dec 2020 | $0M | -28.0% | $-11M | $-11M | -3116.7% |
| Dec 2018 | $1M | — | $-11M | $-10M | -2060.0% |
| Dec 2017 | — | — | $-11M | $-11M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-7M | $0M | $-7M | $0.25 | — |
| Dec 2024 | $-7M | $0M | $-7M | $0.25 | — |
| Dec 2023 | $-7M | $0M | $-7M | $0.31 | — |
| Dec 2022 | $-13M | $0M | $-13M | $0.45 | — |
| Dec 2021 | $-9M | $0M | $-9M | $0.47 | — |
| Dec 2020 | $-11M | $0M | $-11M | $0.67 | — |
| Dec 2018 | $-10M | $0M | $-10M | $1.31 | — |
| Dec 2017 | $-5M | $0M | $-5M | $2.49 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 27, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Oct 14, 2026DEF 14AProxy statement
- Oct 6, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 18, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 7, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 28, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Directors or officers changed
- Jul 16, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- Jun 3, 2026DEF 14AProxy statement
- May 8, 202610-QQuarterly report · period to Mar 2026
Official filings of Entera Bio Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-12 M
- Net income
- $-11 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $16 M
- Total liabilities
- $3 M
- Total equity
- $13 M
As of December-2025
Top 46 institutional investors in Entera Bio Ltd.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BVF Inc/il | 17,052,893 | +14,627,893 (+603.21%) | 9.79% | $50 M | Nov 16, 2026 |
| 2 | Vivo Capital, LLC | 12,254,901 | New | 7.04% | $36 M | Nov 13, 2026 |
| 3 | TCG Crossover Management, LLC | 12,254,901 | New | 7.04% | $36 M | Nov 16, 2026 |
| 4 | Spruce Street Capital LP | 11,213,455 | New | 6.44% | $33 M | Nov 13, 2026 |
| 5 | Commodore Capital LP | 7,352,941 | New | 4.22% | $21 M | Nov 16, 2026 |
| 6 | Seven Fleet Capital Management LP | 6,862,744 | +6,671,390 (+3486.41%) | 3.94% | $20 M | Nov 16, 2026 |
| 7 | Siren, L.L.C. | 6,000,000 | +5,263,543 (+714.71%) | 3.45% | $17 M | Nov 12, 2026 |
| 8 | Knoll Capital Management, LLC | 5,832,038 | -49,841 (-0.85%) | 3.35% | $17 M | Nov 16, 2026 |
| 9 | Driehaus Capital Management LLC | 5,170,284 | New | 2.97% | $15 M | Nov 16, 2026 |
| 10 | Venrock Adviser, LLC | 5,106,337 | New | 2.93% | $15 M | Nov 16, 2026 |
| 11 | Ra Capital Management, L.P. | 4,901,960 | New | 2.81% | $14 M | Nov 16, 2026 |
| 12 | Logos Global Management LP | 4,411,764 | New | 2.53% | $13 M | Nov 16, 2026 |
| 13 | Catalio Capital Management, LP | 3,921,568 | New | 2.25% | $11 M | Nov 16, 2026 |
| 14 | Perceptive Advisors LLC | 3,431,372 | New | 1.97% | $10 M | Nov 16, 2026 |
| 15 | Nantahala Capital Management, LLC | 3,004,848 | New | 1.73% | $9 M | Nov 13, 2026 |
| 16 | NEXTBio Capital Management LP | 2,923,937 | New | 1.68% | $9 M | Nov 13, 2026 |
| 17 | Ameriprise Financial Inc | 2,682,285 | New | 1.54% | $8 M | Nov 16, 2026 |
| 18 | ADAR1 Capital Management, LLC | 2,625,980 | New | 1.51% | $8 M | Nov 16, 2026 |
| 19 | Adage Capital Partners GP, L.L.C. | 2,450,980 | New | 1.41% | $7 M | Nov 16, 2026 |
| 20 | Deep Track Capital, LP | 2,450,980 | New | 1.41% | $7 M | Nov 16, 2026 |
| 21 | Woodline Partners LP | 1,404,901 | New | 0.81% | $4 M | Nov 16, 2026 |
| 22 | Foresite Capital Management VI LLC | 1,225,490 | New | 0.70% | $4 M | Nov 16, 2026 |
| 23 | Affinity Asset Advisors, LLC | 934,412 | New | 0.54% | $3 M | Nov 13, 2026 |
| 24 | SummitTX Capital, L.P. | 662,079 | New | 0.38% | $2 M | Nov 16, 2026 |
| 25 | Parkman Healthcare Partners LLC | 298,791 | +24,294 (+8.85%) | 0.17% | $1 M | Nov 16, 2026 |
Show all 46: investors 26 to 46
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | PNC Financial Services Group, Inc. | 273,031 | 0 (0.00%) | 0.16% | $1 M | Nov 6, 2026 |
| 27 | Diadema Partners LP | 245,098 | +221,838 (+953.73%) | 0.14% | $1 M | Nov 16, 2026 |
| 28 | Marshall Wace, LLP | 210,747 | New | 0.12% | $1 M | Nov 13, 2026 |
| 29 | Geode Capital Management, LLC | 178,259 | +148,351 (+496.02%) | 0.10% | $1 M | Nov 6, 2026 |
| 30 | Schonfeld Strategic Advisors LLC | 162,694 | +103,823 (+176.36%) | 0.09% | $0 M | Nov 16, 2026 |
| 31 | Jane Street Group, LLC | 157,857 | +140,526 (+810.84%) | 0.09% | $0 M | Nov 12, 2026 |
| 32 | Renaissance Technologies LLC | 144,900 | -223,947 (-60.72%) | 0.08% | $0 M | Nov 12, 2026 |
| 33 | Citadel Advisors LLC | 122,438 | +83,634 (+215.53%) | 0.07% | $0 M | Nov 16, 2026 |
| 34 | HighTower Advisors, LLC | 77,382 | +2,809 (+3.77%) | 0.04% | $0 M | Nov 10, 2026 |
| 35 | XTX Topco Ltd | 74,040 | +53,481 (+260.13%) | 0.04% | $0 M | Nov 16, 2026 |
| 36 | Persistent Asset Partners Ltd | 61,060 | +55,179 (+938.26%) | 0.04% | $0 M | Nov 13, 2026 |
| 37 | Signature Estate & Investment Advisors LLC | 47,328 | 0 (0.00%) | 0.03% | $0 M | Oct 13, 2026 |
| 38 | Jpmorgan Chase & Co | 41,896 | +1,013 (+2.48%) | 0.02% | $0 M | Nov 12, 2026 |
| 39 | Gem Investment Advisors, LLC | 19,135 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 40 | UBS Group AG | 11,617 | -1,106 (-8.69%) | 0.01% | $0 M | Nov 10, 2026 |
| 41 | Virtu Financial LLC | 10,259 | -26,662 (-72.21%) | 0.01% | $0 M | Nov 17, 2026 |
| 42 | Morgan Stanley | 8,771 | +8,271 (+1654.20%) | 0.01% | $0 M | Nov 13, 2026 |
| 43 | Caitong International Asset Management Co., Ltd | 823 | New | 0.00% | $0 M | Oct 29, 2026 |
| 44 | Tower Research Capital LLC (TRC) | 65 | New | 0.00% | $0 M | Nov 16, 2026 |
| 45 | Group One Trading LLC | 51 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 46 | SBI Securities Co., Ltd. | 1 | New | 0.00% | $0 M | Oct 22, 2026 |
Insider trading at Entera Bio Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Geno J. GermanoDirector | Grant or award | +25,014 | — | — | 65,014 | Form 4 |
| filed | Haya TaitelDirector | Grant or award | +20,790 | — | — | 119,269 | Form 4 |
| filed | Steven D. RubinDirector | Grant or award | +19,117 | — | — | 34,117 | Form 4 |
| filed | Yonatan MalcaDirector | Grant or award | +22,815 | — | — | 100,231 | Form 4 |
| filed | Sean EllisDirector | Grant or award | +20,034 | — | — | 208,132 | Form 4 |
| filed | Miranda Jayne ToledanoChief Executive Officer, Director | Grant or award | +347,567 | — | — | 774,142 | Form 4 |
| filed | Miranda Jayne ToledanoChief Executive Officer, Director | Grant or award | +72,993 | — | — | 847,135 | Form 4 |
| filed | Hillel GalitzerChief Operating Officer | Grant or award | +72,993 | — | — | 163,566 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Entera Bio Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-07-27 13:57 UTC, code LUDP, resumed 14:02 UTC
- 2026-06-22 16:17 UTC, code LUDP, resumed 16:27 UTC
Fails to deliver
- : 2,962 shares at $3.12
- : 1,239 shares at $2.86
- : 12,603 shares at $2.92
- : 2,994 shares at $3.02
- : 326 shares at $3.05
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Entera Bio Ltd. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median41.5×Price to book 41.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-1.4%Free cash flow is -1.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.25 vs 0.25Diluted EPS 0.25 in fiscal 2025 against 0.25 the year before (report's currency).
- ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$11 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-108.0%-108.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities7.0×Current ratio 6.95 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.7%Diluted shares up 22.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Entera Bio Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.0−76.8%100% | 0.2—100% | 0−100%— | 0.1−76.5%100% | 0.6+56.4%100% | 0.4+54.7%100% | 0.2−52.8%100% | 0.5—100% | — | — | |
| Cost of revenue | 0.0−75.6%100% | 0.2—95.0% | 0−100%— | 0.1−72.9%75.4% | 0.4+24.3%65.3% | 0.3r0.2+42.9%82.2% | 0.2—89.0% | — | — | — | |
| Gross profit | 0−100%0.0% | 0.0—5.0% | 0−100%— | 0.0−83.3%24.6% | 0.2+205%34.7% | 0.1—17.8% | — | — | — | — | |
| Research and development | 6.0+33.5%14295% | 4.5−0.2%2486% | 4.5−22.9%— | 5.8−13.6%4364% | 6.8+6.1%1186% | 6.4r6.4−11.3%1748% | 7.2−15.5%3050% | 8.5+208%1704% | 2.8+4.5%— | 2.6—— | |
| Selling, general and administrative | 0.4+17.1%948% | 0.3—188% | — | — | — | — | — | — | — | — | |
| General and administrative | 5.5+8.4%13155% | 5.1+15.0%2815% | 4.4−38.9%— | 7.3+27.5%5413% | 5.7+17.3%996% | 4.9—1329% | — | — | — | — | |
| Operating expenses | 12+20.2%27450% | 9.6+7.9%5301% | 8.9−31.9%— | 13+5.1%9739% | 12+10.5%2174% | 11—3078% | — | — | — | — | |
| Operating income | −12—−27450% | −9.6—−5296% | −8.9—— | −13—−9714% | −12—−2140% | −11r−11—−3060% | −11—−4853% | −11—−2172% | −11—— | −5.4—— | |
| Other non-operating income (expense) | 0.1+55.2%214% | 0.1+87.1%32.0% | 0.0−62.7%— | 0.1—61.9% | −0.0—−5.1% | −0.0—−7.7% | — | — | — | — | |
| Income before tax | −11—−27236% | −9.5—−5264% | −8.9—— | −13—−9652% | −12—−2145% | −11r−10.0—−3067% | −11—−4574% | −10—−2061% | — | — | |
| Income tax | 0−100%0.0% | 0.0−51.7%7.7% | 0.0−78.8%— | 0.1—102% | −0.1−395%−10.3% | 0.0—5.5% | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | −10.0—−2735% | −11—−4574% | −10—−2061% | −11—— | −1.2—— | |
| Net income attributable to shareholders | −11—−27236% | −9.5—−5271% | −8.9—— | −13—−9754% | −12—−2134% | −11—−3073% | — | — | — | — | |
| Earnings per share, basic | 0.250.0%— | 0.25−19.4%— | 0.31−31.1%— | 0.45−4.3%— | 0.47−29.9%— | 0.67r0.54−24.7%— | 0.89−31.5%— | 1.30−47.8%— | 2.49+822%— | 0.27—— | |
| Earnings per share, diluted | 0.250.0%— | 0.25−19.4%— | 0.31−31.1%— | 0.45−4.3%— | 0.47−29.9%— | 0.67r0.55−24.7%— | 0.89−32.1%— | 1.31−47.4%— | 2.49+219%— | 0.78—— | |
| Shares, weighted average (basic) | 46+22.7%— | 38+29.8%— | 29+0.7%— | 29+10.2%— | 26+41.9%— | 18+51.6%— | 12+52.7%— | 8.0+77.2%— | 4.5+0.4%— | 4.5—— | |
| Shares, weighted average (diluted) | 46+22.7%— | 38+29.8%— | 29+0.7%— | 29+10.2%— | 26+41.9%— | 18r19+51.6%— | 12+52.1%— | 8.0+77.8%— | 4.5−33.5%— | 6.8—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.1−17.9%44.4% | 8.7−21.4%92.2% | 11−10.5%93.7% | 12−50.6%93.8% | 25+190%95.8% | 8.6−43.5%88.4% | 15r15+103%91.1% | 7.5−36.1%56.3% | 12+182%88.5% | 4.2—— | |
| Receivables | 0−100%0.0% | 0.1—1.3% | 0−100%0.0% | 0.2+34.4%1.9% | 0.2−28.2%0.7% | 0.3−8.3%2.6% | 0.3−61.7%1.7% | 0.7—5.4% | — | — | |
| Other current assets | 0.1r0.4−42.5%0.7% | 0.2r0.2−21.8%2.0% | 0.2r0.2−19.0%2.0% | 0.3r0.3+15.7%2.2% | 0.3−2.7%1.0% | 0.3r0.1+169%2.7% | 0.1+7.8%0.6% | 0.1−43.4%0.7% | 0.2—1.2% | — | |
| Current assets | 15+70.5%95.7% | 9.0−20.3%95.5% | 11−12.4%95.7% | 13−49.3%97.9% | 25+178%97.5% | 9.1−41.7%93.7% | 16+25.4%93.6% | 12+0.4%93.4% | 12—93.5% | — | |
| Property, plant and equipment | 0.1+135%0.8% | 0.1−43.0%0.6% | 0.1−28.1%0.8% | 0.1−10.9%1.1% | 0.2−18.8%0.6% | 0.2−5.0%2.0% | 0.2−9.8%1.2% | 0.2+8.2%1.7% | 0.2—1.6% | — | |
| Right-of-use (leased) assets | 0.5+69.1%2.9% | 0.3−29.1%2.9% | 0.4+331%3.3% | 0.1−62.3%0.7% | 0.2−36.1%0.9% | 0.4r0.4+43.8%3.8% | 0.3+51.2%1.6% | 0.2—1.3% | — | — | |
| Other intangible assets | — | — | — | — | — | 0.60.0%6.2% | 0.6−7.1%3.6% | 0.7−0.5%4.9% | 0.7—4.9% | — | |
| Non-current assets | 0.7+66.3%4.3% | 0.4−17.7%4.5% | 0.5+82.7%4.3% | 0.3−57.8%2.1% | 0.7+7.3%2.5% | 0.6r1.2−42.5%6.3% | 1.1+21.9%6.4% | 0.9+1.6%6.6% | 0.9—6.5% | — | |
| Total assets | 16+70.3%100% | 9.4−20.2%100% | 12−10.4%100% | 13−49.5%100% | 26+167%100% | 9.7r10−41.8%100% | 17+25.2%100% | 13+0.5%100% | 13—100% | — | |
| Accounts payable | 0.4+239%2.8% | 0.1+59.0%1.4% | 0.1+388%0.7% | 0.0−89.8%0.1% | 0.2+1.2%0.6% | 0.2r1.3−88.0%1.7% | 1.4+25.7%8.2% | 1.1−23.5%8.2% | 1.4—10.7% | — | |
| Current liabilities | 2.2+87.3%13.8% | 1.2+7.8%12.5% | 1.1−18.6%9.3% | 1.3−57.6%10.2% | 3.2+71.7%12.2% | 1.8r3.3−59.9%18.9% | 4.6+45.3%27.5% | 3.2r1.8+56.4%23.7% | 2.0—15.2% | — | |
| Long-term debt | — | — | — | — | — | — | — | — | 3.9—29.3% | — | |
| Lease liabilities (non-current) | 0.3+155%1.6% | 0.1−60.2%1.1% | 0.3—2.2% | 0−100%0.0% | 0.1−49.4%0.5% | 0.2+99.2%2.5% | 0.1—0.7% | — | — | — | |
| Non-current liabilities | 0.7+414%4.3% | 0.1−53.5%1.4% | 0.3+800%2.4% | 0.0−87.7%0.2% | 0.3−29.6%1.0% | 0.4r0.3+93.2%3.8% | 0.2+195%1.1% | 0.1r1.4−99.8%0.5% | 43—322% | — | |
| Total liabilities | 2.9+121%18.1% | 1.3−5.0%14.0% | 1.4+0.4%11.7% | 1.4−59.9%10.5% | 3.4+54.7%13.2% | 2.2r3.6−53.8%22.8% | 4.8+48.3%28.6% | 3.2−92.8%24.2% | 45—338% | — | |
| Retained earnings | −125—−784% | −114—−1213% | −104—−887% | −95—−727% | −82—−317% | −70r−73—−722% | −63—−377% | −52—−391% | −42—−315% | — | |
| Shareholders' equity | 13+62.1%81.9% | 8.1−22.2%86.0% | 10−11.6%88.3% | 12−47.9%89.5% | 23+200%86.8% | 7.5−45.5%77.2% | 14—82.5% | — | — | — | |
| Total equity | — | — | — | — | — | 6.7−44.1%68.6% | 12+17.8%71.4% | 10—75.8% | −32—−238% | −25—— | |
| Total liabilities and equity | 16+70.3%100% | 9.4−20.2%100% | 12−10.4%100% | 13−49.5%100% | 26+167%100% | 9.7r10−41.8%100% | 17+25.2%100% | 13+0.5%100% | 13—100% | — | |
| Shares outstanding | 46+18.9%— | 39+9.5%— | 35+23.1%— | 29+0.0%— | 29+36.8%— | 21+17.9%— | 18+55.9%— | 11+155%— | 4.50.0%— | 4.5—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | 0.2−5.5%61.6% | 0.2+341%101% | 0.1+25.6%10.8% | 0.0+22.9%— | 0.0—— | |
| Share-based compensation | 2.8+7.6%6548% | 2.6+51.3%1412% | 1.7−24.8%— | 2.2+20.7%1677% | 1.9+107%326% | 0.9−39.2%247% | 1.5+20.3%628% | 1.2−74.8%247% | 4.9+228%— | 1.5—— | |
| Cash from operating activities | −7.4—−17548% | −6.8—−3767% | −7.3—— | −12—−9328% | −9.1—−1587% | −11r−10—−2892% | −8.9—−3779% | −9.8—−1959% | −4.5—— | −3.1—— | |
| Capital expenditure | −0.1—−255% | −0.0—−1.7% | −0.0—— | −0.0—−35.1% | −0.0—−3.0% | −0.1—−14.5% | −0.0—−16.9% | −0.1—−13.6% | −0.1—— | −0.0—— | |
| Cash from investing activities | −0.1—−255% | −0.0—−1.7% | −0.0—— | −0.1—−76.1% | −0.0—−3.0% | −0.1r−0.1−101%−14.5% | 3.9—1672% | −4.1−506%−814% | 1.0—— | −1.1—— | |
| Debt issued | — | — | — | — | — | — | — | — | — | 7.2—— | |
| Debt repaid | — | — | — | — | — | — | — | — | −1.0—— | — | |
| Shares issued | 6.3+57.9%14890% | 4.0+79100%2188% | 0.0—— | 0−100%0.0% | 22+584%3819% | 3.2—873% | — | — | 12—— | — | |
| Cash from financing activities | 14+206%32643% | 4.5−25.8%2473% | 6.0+46331%— | 0.0−99.9%9.7% | 25+527%4445% | 4.1r3.9−68.0%1110% | 13+31.5%5361% | 9.6−13.4%1925% | 11+53.9%— | 7.2—— | |
| Exchange-rate effect on cash | −0.0—−85.7% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Change in cash | 6.2—14755% | −2.3—−1296% | −1.3—— | −13−177%−9394% | 16—2855% | −6.6r−6.6−185%−1797% | 7.7—3254% | −4.2−156%−848% | 7.6+156%— | 3.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0−100%— | 0—— | 0—— | 0−100%— | 0*−100%— | 0−100%— | 0−100%— | 0.0—100% | 0.1*—100% | 0.0—100% | 0.1—100% | 0—— | 0*—— | |
| Cost of revenue | 0−100%— | 0—— | 0—— | 0−100%— | 0*−100%— | 0−100%— | 0−100%— | 0.0—100% | 0.1*—100% | 0.0—100% | 0.0—84.2% | 0—— | 0*—— | |
| Gross profit | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0−100%— | 0—0.0% | 0*—0.0% | 0—0.0% | 0.0—15.8% | — | 0*—— | |
| Research and development | 12+120%— | 4.9+200%— | 3.2+111%— | 2.3+100%— | 1.7*+43.0%— | 1.6+11.2%— | 1.5+40.0%— | 1.1+52.8%2674% | 1.2*+20.1%1465% | 1.5—3517% | 1.1—1905% | 0.7—— | 1.0*—— | |
| Selling, general and administrative | 0.5+5.2%— | 0.2+33.1%— | 0.1+20.4%— | 0.1+4.1%— | 0.1*−43.8%— | 0.1r0.1+90.3%— | 0.1−23.1%— | 0.1—293% | 0.1*—117% | 0.1—148% | 0.1—235% | — | — | |
| General and administrative | 6.3+18.3%— | 2.3+45.1%— | 1.4+18.6%— | 1.3−10.6%— | 1.3*+16.5%— | 1.6+4.5%— | 1.1+5.5%— | 1.4+8.5%3429% | 1.1*+16.8%1385% | 1.5—3676% | 1.1—1909% | 1.3—— | 1.0*—— | |
| Operating expenses | 18+70.1%— | 7.3+123%— | 4.6+71.0%— | 3.5+38.1%— | 3.0*+30.2%— | 3.3+7.8%— | 2.7+22.7%— | 2.6+24.3%6102% | 2.3*+19.1%2850% | 3.0—7193% | 2.2—3814% | 2.1—— | 2.0*—— | |
| Operating income | −18—— | −7.3—— | −4.6—— | −3.5—— | −3.0*—— | −3.3—— | −2.7—— | −2.6—−6102% | −2.3*—−2850% | −3.0—−7193% | −2.2—−3798% | −2.1—— | −2.0*—— | |
| Other non-operating income (expense) | −11−19435%— | −8.3−14979%— | −2.7−23008%— | 0.0—— | 0.0*—— | 0.1—— | 0.0−40.0%— | −0.0−109%−9.5% | −0.0*—−8.5% | 0—0.0% | 0.0—35.1% | 0.0—— | −0.0*—— | |
| Income before tax | — | — | — | — | — | — | — | — | −2.3*—−2859% | −3.0—−7193% | — | — | −2.0*—— | |
| Income tax | — | — | — | — | — | — | — | — | 0.0*—17.1% | 0—0.0% | — | — | 0*—— | |
| Net income attributable to shareholders | −29—— | −16—— | −7.3—— | −3.5—— | −3.0*—— | −3.2—— | −2.7—— | −2.6—−6112% | −2.4*—−2876% | −3.0—−7193% | −2.1—−3763% | −2.0—— | −2.0*—— | |
| Earnings per share, basic | — | 0.11+57.1%— | 0.14+133%— | 0.07+16.7%— | — | 0.07−12.5%— | 0.060.0%— | 0.06+20.0%— | — | 0.08—— | 0.06—— | 0.05—— | — | |
| Earnings per share, diluted | — | 0.11+57.1%— | 0.14+133%— | 0.07+16.7%— | — | 0.07−12.5%— | 0.060.0%— | 0.06+20.0%— | — | 0.08—— | 0.06—— | 0.05—— | — | |
| Shares, weighted average (basic) | 145+208%— | 145+208%— | 50+7.7%— | 48+10.1%— | — | 47+25.1%— | 47+26.3%— | 43+18.1%— | — | 38—— | 37—— | 37—— | — | |
| Shares, weighted average (diluted) | 145+208%— | 145+208%— | 50+7.7%— | 48+10.1%— | — | 47+25.1%— | 47+26.3%— | 43+18.1%— | — | 38—— | 37—— | 37—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 266—96.0% | 266+3001%96.0% | 11+4.2%58.1% | 4.1−67.1%31.5% | 7.1−17.9%44.4% | 8.6+24.0%49.3% | 11+19.9%55.2% | 13+36.8%58.2% | 8.7−21.4%92.2% | 6.9—89.3% | 9.1—90.2% | 9.2—89.7% | 11—93.7% | |
| Receivables | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1—0.6% | 0.1—1.3% | 0.0—0.5% | 0.1—0.6% | — | 0—0.0% | |
| Other current assets | 0.2—0.1% | 0.2−30.5%0.1% | 0.1−25.0%0.7% | 0.3+55.2%1.9% | 0.1r0.4−42.5%0.7% | 0.3+194%1.5% | 0.2+187%1.0% | 0.2+323%0.8% | 0.2r0.2−21.8%2.0% | 0.1—1.1% | 0.1—0.7% | 0.0—0.4% | 0.2r0.2—2.0% | |
| Current assets | 276—99.8% | 276+1526%99.8% | 19−2.1%97.0% | 12−41.1%95.2% | 15+70.5%95.7% | 17+132%97.7% | 19+101%98.2% | 21+118%98.2% | 9.0−20.3%95.5% | 7.3—94.8% | 9.6—95.6% | 9.8—95.2% | 11—95.7% | |
| Property, plant and equipment | 0.1—0.0% | 0.1+16.7%0.0% | 0.1+53.2%0.6% | 0.1+123%1.0% | 0.1+135%0.8% | 0.1+75.4%0.7% | 0.1+3.9%0.4% | 0.1−34.5%0.3% | 0.1−43.0%0.6% | 0.1—0.8% | 0.1—0.8% | 0.1—0.8% | 0.1—0.8% | |
| Right-of-use (leased) assets | 0.3—0.1% | 0.3+76.8%0.1% | 0.4+90.5%1.9% | 0.4+81.9%3.1% | 0.5+69.1%2.9% | 0.2−38.6%1.1% | 0.2−44.8%1.0% | 0.2−40.4%1.1% | 0.3−29.1%2.9% | 0.3—4.1% | 0.3—3.4% | 0.4—3.7% | 0.4—3.3% | |
| Non-current assets | 0.6—0.2% | 0.6+43.8%0.2% | 0.6+64.0%3.0% | 0.6+66.5%4.8% | 0.7+66.3%4.3% | 0.4−0.2%2.3% | 0.4−19.1%1.8% | 0.4−21.7%1.8% | 0.4−17.7%4.5% | 0.4—5.2% | 0.4—4.4% | 0.5—4.8% | 0.5—4.3% | |
| Total assets | 277—100% | 277+1492%100% | 19−1.0%100% | 13−39.2%100% | 16+70.3%100% | 17+125%100% | 20+96.0%100% | 22+111%100% | 9.4−20.2%100% | 7.7—100% | 10—100% | 10—100% | 12—100% | |
| Accounts payable | 0.4—0.1% | 0.4+88.0%0.1% | 0.6+50.1%3.0% | 0.3+104%2.1% | 0.4+239%2.8% | 0.2+17.4%1.2% | 0.4+455%1.9% | 0.1+103%0.6% | 0.1+59.0%1.4% | 0.2—2.4% | 0.1—0.7% | 0.1—0.6% | 0.1—0.7% | |
| Current liabilities | 2.2—0.8% | 2.2+37.0%0.8% | 2.1+14.1%10.8% | 1.6−2.9%12.0% | 2.2+87.3%13.8% | 1.6+41.4%9.0% | 1.8+42.5%9.4% | 1.6+44.8%7.5% | 1.2+7.8%12.5% | 1.1—14.4% | 1.3—12.9% | 1.1—10.9% | 1.1—9.3% | |
| Lease liabilities (non-current) | 0.2—0.1% | 0.2+363%0.1% | 0.2+2411%1.2% | 0.3+416%2.0% | 0.3+155%1.6% | 0.0−72.1%0.2% | 0.0−95.0%0.0% | 0.1−77.2%0.2% | 0.1−60.2%1.1% | 0.1—1.9% | 0.2—1.8% | 0.2—2.2% | 0.3—2.2% | |
| Non-current liabilities | 0.6—0.2% | 0.6+0.5%0.2% | 10+1683%51.9% | 0.9+44.8%6.6% | 0.7+414%4.3% | 0.6+238%3.5% | 0.6+171%2.9% | 0.6+135%2.8% | 0.1−53.5%1.4% | 0.2—2.3% | 0.2—2.1% | 0.3—2.5% | 0.3—2.4% | |
| Total liabilities | 2.8—1.0% | 2.8+26.9%1.0% | 12+407%62.7% | 2.4+10.0%18.6% | 2.9+121%18.1% | 2.2+68.6%12.5% | 2.4+60.4%12.3% | 2.2+61.4%10.3% | 1.3−5.0%14.0% | 1.3—16.7% | 1.5—15.0% | 1.4—13.4% | 1.4—11.7% | |
| Retained earnings | −152—−54.8% | −152—−54.8% | −136—−699% | −129—−982% | −125—−784% | −122—−703% | −119—−606% | −116—−539% | −114—−1213% | −112—−1441% | −109—−1082% | −106—−1039% | −104—−887% | |
| Shareholders' equity | 274—99.0% | 274+1700%99.0% | 7.3−57.9%37.3% | 11−44.9%81.4% | 13+62.1%81.9% | 15+136%87.5% | 17+102%87.7% | 19+119%89.7% | 8.1−22.2%86.0% | 6.5—83.3% | 8.5—85.0% | 8.9—86.6% | 10—88.3% | |
| Total liabilities and equity | 277—100% | 277+1492%100% | 19−1.0%100% | 13−39.2%100% | 16+70.3%100% | 17+125%100% | 20+96.0%100% | 22+111%100% | 9.4−20.2%100% | 7.7—100% | 10—100% | 10—100% | 12—100% | |
| Shares outstanding | 174—— | 174+281%— | 49+8.4%— | 47+2.6%— | 46+18.9%— | 46+25.1%— | 45+25.2%— | 45+27.9%— | 39+9.5%— | 37—— | 36—— | 36—— | 35—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 3.8+46.8%— | 1.8*+96.2%— | 0.6*+22.6%— | 0.7+11.3%— | 0.7*+25.4%— | 0.9*−0.1%— | 0.5*−14.9%— | 0.6+30.2%1438% | 0.6*+78.0%690% | 0.9*—2210% | 0.6*—1049% | 0.5—— | 0.3*—— | |
| Cash from operating activities | −16—— | −7.4*—— | −3.5*—— | −3.1—— | −1.8*—— | −2.5*—— | −1.6*—— | −1.4—−3343% | −1.5*—−1789% | −2.2*—−5129% | −1.3*—−2342% | −1.9—— | −2.6*—— | |
| Capital expenditure | −0.1—— | −0.0*—— | −0.0*—— | 0—— | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—−19.0% | −0.0*—−3.7% | 0*—0.0% | 0*—0.0% | 0—— | −0.0*—— | |
| Cash from investing activities | −0.1—— | −0.0*—— | −0.0*—— | 0—— | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—−19.0% | −0.0*—−3.7% | 0*—0.0% | 0*—0.0% | 0—— | −0.0*—— | |
| Shares issued | 0−100%— | 0*−100%— | 0*—— | 0−100%— | 0*−100%— | 0.1*—— | 0*−100%— | 6.2—14721% | 3.3r3.4*—4073% | 0r0*—0.0% | 0.6r0.6*—1088% | 0—— | 0*—— | |
| Cash from financing activities | 272+1522%— | 261*+104464%— | 10.0*—— | 0.1−99.0%— | 0.2*−94.6%— | 0.3*+1823%— | −0.1*−104%— | 13+44357%31755% | 3.2*−46.7%3923% | 0.0*—31.0% | 1.2*—2133% | 0.0—— | 6.0*—— | |
| Exchange-rate effect on cash | −0.0−269%— | −0.0*−117%— | 0.0*—— | 0.0—— | −0.1*—— | 0.0*—— | 0*—— | 0—0.0% | 0*—0.0% | — | — | — | — | |
| Change in cash | — | — | — | — | — | — | −1.7*—— | 12—28393% | 1.7*−48.8%2130% | −2.1*—−5098% | −0.1*—−209% | −1.8—— | 3.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Entera Bio Ltd. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Entera Bio Ltd.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Miranda Toledano | $1.5 M | $1.4 M | $518 K | $223 |
| 2024Miranda Jayne Toledano | $1.1 M | $2.2 M | $485 K | $212 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Entera Bio Ltd.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 6 · Material agreement 4 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K/A | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2026 | $275 M | Private placement after listing | $250 million to $1 billion | 53 | equity, options | SEC |
| Dec 2023 | $7 M | Private placement after listing | $2 to $10 million | 52 | equity, options | SEC |
| Dec 2019 | $14 M | Private placement after listing | $10 to $50 million | 52 | equity, options | SEC |
| Oct 2017 | $2 M | No. 1 | $2 to $10 million | 30 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Discuss Entera Bio Ltd.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 6 November 2026automatic update · Nov 6, 2026
Entera Bio Ltd. announced results on 6 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $16 million.
How Entera Bio Ltd. compares in Biotechnology
- Market cap$543 M · higher than 59% of 726
- Revenue$0 M · higher than 14% of 647
- Revenue growth-77.8% · higher than 7% of 438
- Price / book41.5× · lower than 4% of 534
- FCF yield-1.4% · higher than 83% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Entera Bio Ltd.🇮🇱 | $543 M | — | — | -77.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Entera Bio Ltd.? Verify and update this profile — free
Show Entera Bio Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.